CSBR Stock Analysis: Buy, Sell, or Hold?
CSBR - Champions Oncology, Inc.
$7.13
-0.18 (-2.44%)
▼
5d:
+4.42%
30d:
+3.21%
90d:
+4.73%
BUY
HIGH Confidence
Last Updated: February 2, 2026
Earnings: Mar 10, 2026
Get Alerted When CSBR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CSBR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CSBR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CSBR is currently trading at $7.13, which is considered fair relative to its 30-day fair value range of $6.70 to $7.28. From a valuation perspective, the stock is trading at a premium (Forward PE: 71.3) compared to its historical average (50.0). At these levels, the market is pricing in 12.6% annual earnings growth.
Technical Outlook: Technically, CSBR is in a uptrend. Immediate support is located at $6.62, while resistance sits at $7.71.
Market Sentiment: CSBR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.00 (+68.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CSBR is in a uptrend. Immediate support is located at $6.62, while resistance sits at $7.71.
Market Sentiment: CSBR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.00 (+68.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$6.70 -
$7.28
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.2%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 68.3% below Wall St target ($12.00)
- BULLISH: Expecting earnings turnaround to 12.6% growth with 11.5% revenue growth
Fair Price Analysis
30-Day Fair Range
$6.70 -
$7.28
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$0.66
(9.3%)
Support & Resistance Levels
Support Level
$6.62
Resistance Level
$7.71
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
71.32
Wall Street Target
$12.00
(+68.3%)
Revenue Growth (YoY)
11.5%
Earnings Growth (YoY)
-61.1%
Profit Margin
4.3%
Valuation Premium vs History
+12.6% premium
PE vs Historical
71.3 vs 50.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.6%
(market-implied from PE analysis)
1-Year Target
$8.03
(+13%)
2-Year Target
$9.04
(+27%)
3-Year Target
$10.18
(+43%)
3-Yr Target (if PE normalizes)
(PE: 71→50)
PE COMPRESSION
$7.14
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 71.3, Growth: -16.7%)
$5.20
(+-27%)
Base:
(SPY PE: 22.3, Growth: -16.7%)
$1.63
(-77%)
Bear:
(PE: 19.0, Growth: -16.7%)
$1.38
(-81%)
📈
Valuation based on Current Earnings
Trailing PE: 44.82 | Current EPS (TTM): $0.17
Bull Case
$4.93
(-33%)
Analyst growth -41.2%, PE expands to 49.3
Base Case
$4.48
(-39%)
Market implied -41.2%, PE stable at 44.8
Bear Case
$5.18
(-29%)
Severe decline -20.0%, PE contracts to 38.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 02, 2026 5:58 PM ET
Data refreshes hourly during market hours. Next update: 6:58 PM
Data refreshes hourly during market hours. Next update: 6:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSBR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 64 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
